Boston Scientific (BSX)
(Delayed Data from NYSE)
$75.92 USD
+0.42 (0.56%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $76.14 +0.22 (0.29%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$75.92 USD
+0.42 (0.56%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $76.14 +0.22 (0.29%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth F Momentum D VGM
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Boston Scientific's (BSX) Q3 Earnings In Line, Sales Top
by Zacks Equity Research
Boston Scientific (BSX) has posted impressive Q3 results by delivering revenue growth across all segments.
Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Abbott Labs, Medtronic and Boston Scientific.
MedTech Stock Q3 Earnings Roster for Oct 26: BSX, RMD & More
by Zacks Equity Research
Investors are concerned about the Medical sector that saw a lot of struggle during the first nine months of the year, thanks to the political change and the ongoing policy-restructuring related battle.
EW vs. BCR: Which Stock is Poised for Better Q3 Earnings?
by Zacks Equity Research
Political turmoil and the health policy related battle apart, majority of the MedTech stocks' bottom line is likely to be hurt in the third quarter on escalating costs induced by consecutive hurricanes and Mexico earthquakes.
Will Recall Issue Hurt Boston Scientific (BSX) Q3 Earnings?
by Zacks Equity Research
Although Boston Scientific's (BSX) recent $435-million acquisition of Symetis SA might drive its IC business, the company's full recovery post a primary product recall may however, take time.
Boston Scientific Grows on New Products, Currency Woe Ails
by Zacks Equity Research
Boston Scientific (BSX) is gaining traction on product launch and accretive acquisitions. Yet an unfavorable currency movement is a major dampener.
Boston Scientific's Apama Deal to Boost Electrophysiology Arm
by Zacks Equity Research
Boston Scientific's (BSX) Apama Medical addition is expected to strengthen its suite of arrhythmia solutions under the Electrophysiology sub-segment.
Abbott's Ellipse ICD Receives FDA Approval for MRI Scans
by Zacks Equity Research
Abbott's (ABT) Rhythm Management segment to gain traction with the latest FDA approval of Ellipse ICD for MR-conditioning labeling.
Boston Scientific's Resonate Devices Boost Cardiac Rhythm Arm
by Zacks Equity Research
Boston Scientific (BSX) is consistently strengthening its Cardiac Rhythm Management segment.
Medtronic (MDT) Initiates Study on CoreValve Evolut PRO TAVI
by Zacks Equity Research
Medtronic (MDT) to initiate FORWARD PRO Clinical Study for evaluating the safety standards of self-expanding TAVI system over longer-term.
Boston Scientific MultiSENSE Study on HeartLogic Positive
by Zacks Equity Research
Boston Scientific (BSX) positive clinical trial data on HeartLogic should boost the Rhythm Management segment.
Boston Scientific Grows on Innovation, Buyouts Amid Woes
by Zacks Equity Research
While unfavorable foreign exchange continues to raise concerns, Boston Scientific (BSX) stands steadily on growth track with Symetis acquisition and FDA-approved products.
Abbott's (ABT) FDA Nod for LVAD Boosts Medical Devices Arm
by Zacks Equity Research
Abbott Laboratories' (ABT) receipt of FDA approval for its Full MagLev HeartMate 3 LVAD strengthens one of its major business segments.
Boston Scientific (BSX) Tops Q2 Earnings & Sales, View Up
by Zacks Equity Research
Boston Scientific's (BSX) Q2 results gain on balanced segmental growth. Currency remains a dampener though.
Boston Scientific (BSX) Exceeds Q2 Earnings, Sales Estimates
by Zacks Equity Research
Boston Scientific (BSX) rides high on acquisitions and FDA approvals.
Med-Products' Q2 Earnings Roster for Jul 27: ALGN, BSX & More
by Zacks Equity Research
The ongoing conflict related to healthcare policy implementation in the U.S. might get reflected in the Q2 results of these companies.
FDA Approval Widens Medtronic's (MDT) TAVR Platform Reach
by Zacks Equity Research
Medtronic plc (MDT), a well established player in the medical technology, services and solutions space, recently announced FDA approval for the extended use of its self-expanding CoreValve Evolut transcatheter aortic valve replacement (TAVR) platform.
Medtronic (MDT) Launches Resolute Onyx DES Device in Japan
by Zacks Equity Research
Medtronic plc (MDT), a leading global player in medical technology, services and solutions, is set to make another encouraging move with respect to its highest revenue grossing Cardiovascular segment.
Boston Scientific Rides on New Growth Plans amid Headwinds
by Zacks Equity Research
On Jun 29 2017, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).
Top Stock Reports for Halliburton, Boston Scientific & Anheuser-Busch
by Brian Hamilton
Today's Research Daily features new research reports on 16 major stocks, including Halliburton (HAL), Boston Scientific (BSX), and Anheuser-Busch (BUD).
Boston Scientific Wins CE Mark for Vercise Gevia DBS System (revised)
by Zacks Equity Research
Generally, DBS therapy is a surgical procedure of placing a device that stimulates specific areas in the brain using electrical signals.
Boston Scientific Wins CE Mark for Vercise Gevia DBS System
by Zacks Equity Research
Boston Scientific Corporation (BSX) recently won CE mark for its Vercise Gevia Deep Brain Stimulation (DBS) System.
Boston Scientific (BSX) Up 4.4% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Boston Scientific Trades Up on Strong Q1 amid Recall Issues
by Zacks Equity Research
On May 29 2017, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).
Boston Scientific (BSX) BT Study on Asthma Results Positive
by Zacks Equity Research
Boston Scientific Corporation (BSX) recently unveiled positive outcome from the Post Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma (PAS2) study.